or how the Boards of Appeal of the European patent office claimed their independence from the European Commission In a landmark decision published on February 5, 2019, the Board of Appeal of the European patent office (EPO) decided that plants exclusively obtained by an “essentially biological process” could be patentable after all. Case T1063/18 concerns the appeal […]
22 February 2019
Learn more
An update of the situation to the French readers of monthly magazine “BIOFUTUR” (published in December 2017). Read the article: Marion Chajmowicz, BIOFUTUR, May 2017, 386 :51-53 Brevets Crispr/Cas9: une guerre sans fin ?
18 December 2017
Learn more
Protecting an invention in Life Sciences and diagnostics has become more and more tricky in the U.S. An update of the situation to the French readers of monthly magazine “BIOFUTUR”. Read the article: Marion Chajmowicz et Ludovic Le Guen, BIOFUTUR, mars 2017, 384: 52-53, Make US patents great again
15 April 2017
Learn more
However on March 16, 2017, the judges decided that Actelion Pharmaceuticals’ request for invalidating European patent No. 1 200 092 owned by ICOS Corporation had not been timely lodged. The Court referred to the statutory period of limitation which restricts civil actions to “five years following the day on which the owner of a right […]
9 April 2017
Learn more
If you would like more information, please do not hesitate to contact us. Please fill in the online form.
Paris
Cabinet Becker et Associés
25 rue Louis Le Grand
75002 Paris
Métro : Opéra
Parking : Opéra-Meyerbeer
+33 (0)1 53 43 85 00
Aix-en-Provence
Cabinet Becker et Associés
32 cours Mirabeau
13100 Aix-en-Provence
Parking : Mignet